基于人体等效剂量的蟾酥量—效关系探讨

Approach on Ch'an su dosage-effect relationship based on the human equivalent dose

目的：探讨中药材蟾酥的量—效/毒关系。方法：引用相关整体动物有效剂量的文献数据,根据体表面积法换算药材蟾酥的人体等效剂量（HED）。结果：折算蟾酥抗炎的HED为9.8-39.2 mg/日,抗肿瘤HED为53.7-104.7 mg/日,毒性HED为162-585.4 mg/日。结论：蟾酥用于炎症治疗的HED较小,接近甚至低于药典推荐用量（15-30 mg/日）,提示其临床用量具有一定科学、合理性;但分析显示抗肿瘤的HED较高,其上限与蟾酥中毒的HED接近,提示中药材蟾酥用于肿瘤的中医处方剂量需谨慎设计。

AIM： To approach the clinical dosage- effect relationship of Ch＇ an su. METHODS： The paper was performed by quoting literature data with animal effective doses to converse Ch＇an su human equivalent dose （HED） range according to body surface area law. RESULTS： Ch＇ an su anti-inflammation HED was 9.8 - 39.2 mg/d, Ch＇ an su anti-tumor HED was 53.7 - 104.7 mg/d, the adverse reaction HED was 162- 585.4 mg/d. CONCLUSION： Ch＇ an su anti-inflammation HED was smaller than the recommended dosage （ 15 - 30 mg/d）, which suggested the clinical dosage is scientific and reasonable. But the anti-tumor HED was high, the upper limit and the HED dosege of secnetio bufonis poisoning were close, which suggested the dosage of Ch＇ an su for the clinical treatment of tumor should be designed cautiously.